GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » EBITDA per Share

908 Devices (908 Devices) EBITDA per Share : $-1.04 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is 908 Devices EBITDA per Share?

908 Devices's EBITDA per Share for the three months ended in Mar. 2024 was $-0.30. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.04.

During the past 3 years, the average EBITDA per Share Growth Rate was 19.30% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -23.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for 908 Devices's EBITDA per Share or its related term are showing as below:

MASS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.9   Med: -22   Max: 19.3
Current: 19.3

During the past 6 years, the highest 3-Year average EBITDA per Share Growth Rate of 908 Devices was 19.30% per year. The lowest was -36.90% per year. And the median was -22.00% per year.

MASS's 3-Year EBITDA Growth Rate is ranked better than
66.1% of 708 companies
in the Medical Devices & Instruments industry
Industry Median: 8 vs MASS: 19.30

908 Devices's EBITDA for the three months ended in Mar. 2024 was $-9.66 Mil.

During the past 3 years, the average EBITDA Growth Rate was -45.70% per year. During the past 5 years, the average EBITDA Growth Rate was -44.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 6 years, the highest 3-Year average EBITDA Growth Rate of 908 Devices was -42.70% per year. The lowest was -55.80% per year. And the median was -45.70% per year.


908 Devices EBITDA per Share Historical Data

The historical data trend for 908 Devices's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices EBITDA per Share Chart

908 Devices Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
Get a 7-Day Free Trial -0.56 -2.01 -0.74 -1.01 -1.06

908 Devices Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.27 -0.26 -0.22 -0.30

908 Devices EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

908 Devices's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-34.025/32.239
=-1.06

908 Devices's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-9.659/32.711
=-0.30

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


908 Devices  (NAS:MASS) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


908 Devices EBITDA per Share Related Terms

Thank you for viewing the detailed overview of 908 Devices's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


908 Devices (908 Devices) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Boston, MA, USA, 02210
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Executives
Griffith Joseph H. Iv officer: Chief Financial Officer 68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown officer: Chief Technology Officer C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp director, officer: President and CEO C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner officer: VP, General Counsel C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick officer: VP, Product Management & Mktg 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier officer: Chief People Officer 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky officer: Vice President, Commercial C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg officer: Vice President, Government C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt director 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631